UT Southwestern Medical Center Dallas, Texas
Associate Professor in the Department of Internal Medicine Komen Distinguished Chair in Clinical Breast Cancer Research Clinical Director, Breast Cancer Program, Harold C. Simmons Comprehensive Cancer Center
Testing a new combination strategy to reduce toxicity and improve outcomes in triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by early recurrence and high mortality. While chemotherapy remains the backbone of therapy in these patients, the addition of immunotherapy, such as pembrolizumab (KEYTRUDA®), has led to substantial improvements in clinical outcomes for some patients. However, the approved regimen requires four chemotherapy drugs in combination with pembrolizumab, thereby resulting in intense side effects for patients. Furthermore, among the 37 percent of patients who do not benefit from pembrolizumab and chemotherapy, approximately one-third will experience a distant recurrence (metastasis). Dr. McArthur and her team are testing a new immune-based strategy with the aim of reducing toxicity and improving outcomes.
The new therapeutic strategy that Dr. McArthur and her team are investigating stimulates an individual’s immune system to recognize and respond to the specific features of their tumor. They have completed a pilot study of a treatment approach using cryoablation (targeted freezing of tumor cells) combined with immune therapy, which synergize to induce activation of critical and tumor-specific immune cells.
Based on the results of the pilot study, Dr. McArthur and her team are now conducting a phase 2 study with cryoablation plus immune therapy in patients with TNBC and residual disease after conventional chemotherapy. This study has the potential to lead to a new breakthrough in the treatment of patients with high-risk, localized TNBC.
Heather McArthur, MD, MPH joined UT Southwestern Medical Center in 2021 as the Komen Distinguished Chair in Clinical Breast Cancer Research. She is a medical oncologist with a clinical practice dedicated to the care of patients with breast cancer. Her research activities are focused on innovations in the diagnosis and treatment of breast cancer, with a particular interest in novel immune therapy strategies. Dr. McArthur completed formal medical oncology training at the University of British Columbia. There, she was awarded the highly competitive Canadian Association of Medical Oncology/Canadian Institute for Health Research R&D Fellowship which funded an advanced clinical research fellowship at MSKCC. Thereafter, she joined MSKCC as faculty and in that role developed the institutional breast cancer immunotherapy program before joining Cedars-Sinai in 2016. She has a Master’s in Public Health with a focus on clinical trial design from Harvard University and has mentored many medical students, residents, fellows, and junior faculty in the conduct and reporting of several studies – two of which directly informed national (NCCN) treatment guidelines.
Dr. McArthur has designed, conducted, and reported on many studies in breast cancer and has held several leadership positions in the field including US Co-Chair of a Breast International Group Immunotherapy Taskforce, member of an NCI Breast Cancer Immuno-Oncology (IO) Working Group, member of a NCI Breast Cancer IO Task Force, and member of the Alliance for Clinical Trials in Oncology Immunotherapy/Immune Monitoring Working Group. She has served on the ASCO Conquer Cancer Foundation YIA/CDA Grant Selection Committee, the ASCO Breast Cancer Symposium Program Committee, and as a faculty member for the ASCO Annual Meeting Grant Writing Workshop. She is currently on the ASCO Annual Meeting IO Scientific Committee and participates in the ASCO Leadership Development Program. She has served as a reviewer for numerous journals including Science, the New England Journal of Medicine, and Cancer, and has authored more than 70 articles, review articles, invited commentaries, and book chapters on breast cancer.
2013
Please remember BCRF in your will planning. Learn More
